

1 **DOI:** <https://doi.org/10.47391/JPMA.130>

2  
3 **Effects of different polyvinylpyrrolidone iodine concentrations on**  
4 **trismus and swelling following third molar surgery**

5  
6 **Esra Yuce<sup>1</sup>, Omur Dereci<sup>2</sup>, Nazli Altin<sup>3</sup>, Cansugul Efeoglu Koca<sup>4</sup>, Murude**  
7 **Yazan<sup>5</sup>**

8 **1,5** Department of Oral and Maxillofacial Surgery, Biruni University, Istanbul, Turkey;

9 **2** Department of Oral and Maxillofacial Surgery, Eskisehir Osmangazi University, Eskisehir,

10 Turkey; **3** Department of Oral and Maxillofacial Surgery, İstanbul Aydın University,

11 İstanbul, Turkey; **4** Department of Oral and Maxillofacial Surgery, Usak University, Usak,

12 Turkey.

13 **Correspondence:** Esra Yuce. **Email:** dt.esrayuce@gmail.com

14  
15 **Abstract**

16 **Objective:** To compare the clinical efficacy of different povidone iodine  
17 concentrations for the management of postoperative pain and swelling  
18 following mandibular third molar surgery.

19 **Methods:** The randomised, prospective, double-blind and controlled study was  
20 conducted from October 2016 to January 2018 at the Department of Oral and  
21 Maxillofacial Surgery, Faculty of Dentistry, Biruni University, Istanbul,  
22 Turkey, and comprised individuals aged 18-30 years who underwent surgical  
23 removal of pathology-free completely unerupted mandibular lower third  
24 molars. The participants were randomly assigned to four groups: Group I had  
25 saline-only controls, Group II was given 0.5% concentration of povidone  
26 iodine, Group III had 1% concentration of povidone iodine, and Group IV had  
27 3% concentration of povidone iodine. Facial swelling and trismus were assessed  
28 on the 2nd and 7th postoperative days. Data was analysed using SPSS 22.

29 **Results:** Of the 80 patients, 34(42.5%) were males and 46(57.5%) were females  
30 with an overall mean age of  $24.6 \pm 3.68$  years. Each group had 20(25%) subjects.  
31 All three concentrations of povidone iodine provided significant reduction in  
32 postoperative trismus compared to the controls. Trismus was less in Group III  
33 and Group IV compared to Group II up to 7 days after surgery.

34 **Conclusion:** Irrigation with 3% povidone iodine concentration was found to be  
35 more effective in reducing the level of facial swelling after impacted third molar  
36 surgery. (Clinical Trials.gov Identifier: NCT03894722)

37 **Key Words:** Maxillofacial surgery, Third molar, Povidone-Iodine, Swelling,  
38 Tismus

39

#### 40 **Introduction**

41 The surgical extraction of impacted third molars is one of the most frequently  
42 performed procedures in dentoalveolar surgery<sup>1,2</sup>. As part of the human body's  
43 ability to self-heal, characteristic symptoms following third molar extraction,  
44 such as pain, swelling or trismus, may commonly appear to respond favourably  
45 to the surgical trauma which led to patient discomfort during the post-operative  
46 period. Although the risk/benefit analyses are available in literature, there  
47 remains some controversy regarding which specific methods best address  
48 improvements in patient comfort and the enhancement of well-being in the post-  
49 operative period<sup>3</sup>.

50 In spite of difficulties in identifying the main aetiology among various  
51 predisposing factors, various strategies are associated with third molar  
52 surgery<sup>4,5</sup>. Most studies describe the use of topical antimicrobial agents to stave  
53 off any microbial threat during wound-healing<sup>6,7</sup>. Despite warnings  
54 regarding the misuse and overuse of antibiotics that could raise the risk of  
55 developing antimicrobial resistance, there has been a dwindling reliance on  
56 antibiotic prophylaxis or pre-emptive antimicrobial medication for surgery to

57 reduce the incidence of inflammatory complications and impaired wound-  
58 healing<sup>7</sup>.

59 Polyvinylpyrrolidone iodine (PVP-I; povidone-iodine), formed following the  
60 binding of free iodine to PVP, is a highly potent antiseptic water-soluble agent  
61 used for skin preparation before and after surgery. PVP-I shows bactericidal  
62 activity against a wide range of micro-organisms, including bacteria, fungi,  
63 protozoa and viruses. Although PVP does not show any intrinsic antimicrobial  
64 activity, its role in free-iodine delivery directly to bacterial target cell  
65 membranes has been described. In more recent studies, haemostatic, osteogenic  
66 and anti-oedematous effects of PVP-I have been demonstrated with significant  
67 results<sup>5,6,8,9</sup>. Its potent anti-oedematous activity at low concentrations was  
68 associated with the inhibition of human inflammatory mediators such as  
69 histamine, bradykinin, serotonin prostaglandins, leukotrienes and other  
70 substances released into their surroundings by human effector cells immediately  
71 after injury<sup>10</sup>.

72 Exercising precautions with patients undergoing impacted third molar surgery  
73 in the intra-operative phase may allow for a reduction in the rate of  
74 development of post-operative inflammatory complications<sup>11</sup>. It was reported  
75 that PVP-I had haemostatic and anti-oedematous properties with satisfactory  
76 results when used as an irrigation or coolant solution after or during extraction;  
77 however, the ideal concentration of PVP-I for maximal efficacy was not  
78 clarified<sup>5,6,8,11</sup>.

79 The current study was planned to compare the efficacy of different  
80 concentrations of PVP-I in the prevention of postoperative swelling and trismus  
81 when used as a coolant and irrigation solution during the impacted mandibular  
82 third molar surgery.

### 83 **Materials and Method**

84 The randomised, prospective, double-blind and controlled study was conducted  
85 from October 2016 to January 2018 at the Department of Oral and Maxillofacial

86 Surgery, Faculty of Dentistry, Biruni University, Istanbul, Turkey. It comprised  
 87 individuals who underwent surgical removal of pathology-free completely  
 88 unerrupted mandibular lower third molars. After approval from the ethics  
 89 committee of Acibadem University, Istanbul, Turkey, the sample size  
 90 calculation was done on the basis of  $\alpha=5\%$  and power of  $=80\%$  using the  
 91 following formula<sup>5</sup>:

$$92 \quad n = \frac{Z_{1-\alpha/2} + Z_{1-\beta}}{d} \sqrt{\frac{p(1-p)}{d}}$$

93 Those included were aged 18-30 years without systemic diseases, completely  
 94 unerrupted mandibular lower third molars described as class C/1-3 according to  
 95 the Pell-Gregory classification<sup>12</sup>. Those excluded were because of  
 96 pregnancy/lactation, medication usage that could adversely affect the healing  
 97 process, presence of any condition such as inflammation, periodontitis, dental  
 98 abscess in the area of the impacted teeth, smoking, undergoing anti-  
 99 inflammatory or antibiotic drugs therapies <1 week before surgery, history of  
 100 hypersensitivity to iodine, and any thyroid diseases.

101 After taking informed consent, the sample was randomised into four equal  
 102 groups using sequentially-numbered opaque sealed envelopes. Group I was  
 103 taken as control and was subjected only to saline. Further, 10% PVP-I solution  
 104 was diluted with saline to obtain an irrigation solution at different  
 105 concentrations for surgical procedures. Group II was given 0.5% concentration  
 106 of PVP-I (1ml PVP-I /200ml saline); Group III had 1% concentration of PVP-I  
 107 (2ml PVP-I /200ml saline); and Group IV was given 3% concentration of PVP-I  
 108 (6ml PVP-I /200ml saline).

109 In order to standardise the surgical procedure, each patient underwent the same  
 110 surgical technique by the same surgeon. Local anaesthesia of the inferior  
 111 alveolar, lingual and buccal nerves was carried out by using 2% lidocaine with  
 112 1:80,000 epinephrine. A full-thickness buccal mucoperiosteal flap was reflected  
 113 and alveolar bone was removed buccally on the distal aspect of the impacted

114 tooth using a round bur under PVP-I solution or saline irrigation. After single  
115 tooth extraction in each patient, irregular bony margins were smoothed and the  
116 alveolar socket was irrigated with 10ml PVP-I solution in Groups II, III and IV,  
117 and with equal amounts of saline in the control group. The flap was  
118 hermetically sutured with 3-0 silk in all groups. Only analgesic ibuprofen  
119 200mg (1 tablet every 12 hours) and mouth rinse (0.2% chlorhexidine, twice  
120 daily) were prescribed for 7 days. No antibiotics or steroids were administered  
121 to any of the patient. The patients were followed up post-operatively on days 2  
122 and 7.

123 Pre-operatively and post-operatively on days 2 and 7 following the surgical  
124 procedure, facial measurements were recorded in the closed mouth position. All  
125 assessments were done by an attending surgeon blinded to the study in order to  
126 reduce bias.

127 The relationship of mandibular third molar to the ramus of the mandible  
128 according to the Pell-Gregory classification<sup>12</sup> was recorded as a clinical variable  
129 after the operation. The maximum mouth opening and swelling were evaluated  
130 using a digital caliper. The degree of trismus was assessed by measuring the  
131 distance between lower and upper incisal borders of the central incisors. For the  
132 assessment of swelling, three facial lines were measured on the operated side  
133 using several landmarks, such as the external canthus of the eye, the gonion  
134 angle, the lower border of the tragus, soft pogonion, and the mouth commissure  
135 (Figure 1).

136 Statistical analysis was done using SPSS 22. The 4 groups were compared in  
137 terms of baseline descriptive data, including mean age, gender distribution and  
138 relation of tooth to the ramus of the mandible by one-way analysis of variance  
139 (ANOVA), chi-square and Fisher Freeman Halton test respectively to avoid the  
140 interference of confounding variables. Shapiro Wilks test was used to verify the  
141 distribution for normality. Inter-group comparisons were analysed with one-way  
142 ANOVA and the Tukey honestly significant difference (HSD) test was used to

143 identify which group samples differed significantly from the other groups. For  
144 repeated measurements, analysis of variance and Bonferroni's test were  
145 performed.  $P < 0.05$  was considered significant.

146

## 147 **Results**

148 Of the 80 patients, 34(42.5%) were males and 46(57.5%) were females with an  
149 overall mean age of  $24.6 \pm 3.68$  years. Each group had 20(25%) subjects. No  
150 significant differences in mean age, gender distribution and relation of tooth to  
151 the ramus of the mandible were identified among the groups (Table 1).

152 There was no significant difference between mean pre-operative interincisal  
153 mouth opening measurements among the groups ( $p > 0.05$ ). Trismus was assessed  
154 with regard to reduction in the maximum interincisal distance of each patient  
155 between the pre-operative period and on post-operative days 2 and 7. There was  
156 a significant difference between Group I and the other three groups on  
157 postoperative days 2 and 7 ( $p < 0.05$ ). Mouth opening measurements in groups  
158 irrigated with PVP-I was greater than the control group ( $p < 0.05$ ). In groups  
159 irrigated with PVP-I, the limitation of the mouth opening on average on  
160 postoperative days 2 and 7 was less in Group III and Group IV compared to  
161 Group II. Although there was no significant difference between Group III and  
162 Group IV, the differences between study groups and the control group were  
163 statistically significant (Table 2).

164 Swelling was expressed as the increase in the tragus–commissure, canthus–  
165 gnathion and tragus–pogonion lines on postoperative days 2 and 7 compared to  
166 the baseline measurements. In all groups, mean facial swelling was significantly  
167 increased on postoperative day 2, and a gradual decreasing in swelling was  
168 observed from day 2 to day 7. The length of the tragus–commissure line on  
169 postoperative days 2 and 7 in Group IV was significantly less than the other  
170 groups ( $p < 0.05$ ). Compared to the intervention groups, the increment in  
171 measurements of the tragus–pogonion line on postoperative days 2 and 7 were

172 greater in the control group at each time point ( $p < 0.05$ ). The intervention groups  
173 showed considerably better reduction in the increase. Differences between the  
174 pre-operative and post-operative values on days 2 and 7 were greater in groups  
175 I, II and III, while on the 7th post-operative day, the average score was  
176 significantly similar to the pre-operative values in Group IV ( $p < 0.05$ ). Irrigation  
177 in Group IV was more effective in reducing the level of facial swelling on  
178 postoperative days 2 and 7 after impacted third molar surgery (Table 3).

179

## 180 **Discussion**

181 Surgical procedures are routinely followed by an inflammatory process, which  
182 is the first line of protective response by a tissue to injury<sup>3,13</sup>. It is a well-known  
183 fact that the intensity of associated pain reaches nearly its maximum for a  
184 duration of about 3-5 hours and it may last as long as 2-3 days; and relief may  
185 be achieved within 7 days after surgery<sup>14,15</sup>. Depending on the amount of hard-  
186 and/or soft-tissue trauma based on the anatomical position of the third molar,  
187 the incidence of swelling peaks 48-72 hours after surgery, and post-operative  
188 inflammation can potentially persist with a decreasing trend 5-7 days after  
189 surgery<sup>14</sup>. Inflammatory complications are the main cause of increased post-  
190 operative patient discomfort and delayed healing process in third molar surgery.  
191 Many studies aimed at controlling acute inflammation and/or minimising the  
192 infection risk have relied on the efficacy of drugs, such as antibiotics,  
193 corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), at various  
194 stages of surgery or processing dealing with irrigation and removal of debris  
195 and organic matter using various disinfectant solutions<sup>13,16</sup>.

196 PVP-I is a broad-spectrum and fast-acting antiseptic solution that has been  
197 shown to exhibit a wide range of bactericidal, as well as virucidal, fungicidal  
198 and protozoicidal activities by rapidly releasing the free iodine that penetrates  
199 into, respectively, micro-organisms, cytoplasmic membrane and contents<sup>5,8,17</sup>. In  
200 addition to its antiseptic property, Asimakopoulos et al. reported its anti-

201 oedematous effect as a phenomenon investigated incidentally during the  
202 surgical removal of the lower third molar under irrigation with dilute povidone-  
203 iodine solution to investigate primarily haemostatic property<sup>18</sup>. The beneficial  
204 impact of dilutions from PVP-I stock solutions on preventing post-operative  
205 complications is expected, but actual clinical efficacy is unknown<sup>19</sup>. In  
206 vitro and in vivo studies have shown that PVP-I could limit the function of the  
207 inflammasomes in such a way as to alter prostaglandin synthesis by decreasing  
208 leukocyte chemotaxis and its extravasation. It was also shown that the presence  
209 of iodine leads to the destruction of tissue-damaging factors and cytokines,  
210 thereby interfering with the inflammatory process and favouring wound-  
211 healing<sup>4,20,21</sup>.

212 PVP-I solution was selected for this study because it has excellent microbial  
213 inhibition and acts as an anti-oedematous agent, has minimal allergic and toxic  
214 potential, and enhances osteogenic proliferation and differentiation in an  
215 osteoblast-like cell line through the early post-operative period<sup>22,23</sup>.

216 Ample research on PVP-I has provided promising evidence regarding its potent  
217 chemical properties and biological activities for new applications in  
218 many medical fields, including wound-healing, ophthalmological treatment,  
219 inhalation therapy for respiratory tract diseases, intra-articular infections,  
220 prophylaxis following joint surgery, and allograft transplantation<sup>21</sup>.

221 A 2011 study determined a significant decrease in the appearance of post-  
222 operative swelling when applied PVP-I coolant at a concentration of 0.5mg/mL  
223 in impacted third molar surgery<sup>24</sup>. It reported that low concentrations of PVP-I  
224 showed an anti-oedematous effect via impeding chemotactic responses of  
225 neutrophils activated by leukotriene B4 production. The current stud also  
226 attempted to investigate the use of povidone-iodine solution using the technique  
227 described in literature<sup>24</sup>. The PVP-I used here is a commercially available  
228 product, which simplifies its use in future clinical applications, making this  
229 procedure easy, inexpensive and convenient for both the surgeon and the



230 patient, due to its potential to reduce the overuse of antimicrobial prophylaxis  
231 and anti-inflammatory agents after impacted third molar surgery.

232 Many different methods, including computed tomography (CT) scans, three-  
233 dimensional (3D) laser-scanning devices, photographs etc., may be used to  
234 assess facial swelling following the dentoalveolar surgery. A study took  
235 measurements by marking 4 fixed points (oral commissure, tragus, external  
236 canthus, gonion and pogonion,) and 3 surgical baselines to evaluate oedema for  
237 the extension of swelling<sup>2</sup>. To compare oedema, the present study used the  
238 anatomical markers described by the earlier study in the closed mouth position  
239 for reasons of validity, ease, low cost, and repeatability of the method<sup>2</sup>.

240 One study assessed the anti-inflammatory effect of liposomal hydrogel with 3%  
241 PVP-I using several established in vitro tests, and found that PVP-I had a  
242 beneficial effect on inflammation supported by iodine's free radical scavenging  
243 that inhibited mast cell activity and polymorphonuclear neutrophil production of  
244 reactive oxygen species<sup>4</sup>.

245 A study in 2015 compared 0.5mg/mL concentrated solution of PVP-I and saline  
246 as a coolant and irrigant during surgical extractions of impacted third molars,  
247 and found that PVP-I solution had considerably better efficacy than saline in  
248 controlling swelling and trismus, but that there was no significant difference in  
249 pain control between the two irrigants<sup>5</sup>. Pain was not evaluated in the present  
250 study as an objective result cannot be obtained when taking into account its  
251 subjective nature.

252 It was reported in many studies that oral-rinsing with PVP-I-hydrogen-  
253 peroxide-containing compounds provide an important decrease in bleeding and  
254 inflammation in gingivitis patients<sup>25</sup>. In 2009, a study performed sub-gingival  
255 irrigation of the periodontal pockets with 10% povidone-iodine solution to  
256 gauge the efficacy of basic mechanical periodontal therapy and iodophor  
257 solutions as an adjunctive treatment on patients with severe chronic

258 periodontitis, and found improved reduction of gingival inflammation in the  
259 regions treated with 10% PVP-I solution irrigation<sup>26</sup>.

260 In vivo research using a concentration of 0.5-10% PVP-I solution for antiseptic  
261 and anti-inflammatory purposes, including the irrigation of surgical wounds and  
262 preparation for surgical interventions, described these dilutions as combining  
263 rapid onset, fast acting, high potency, safety and time-saving without serious  
264 side effects<sup>5,16,21,25</sup>. PVP-I solution of 1% concentration was defined as the most  
265 viable dilution for wound irrigation by a study<sup>24</sup>; however, the ideal  
266 concentration of PVP-I for maximal efficacy was not clarified<sup>8,17</sup>. The antiseptic  
267 and anti-inflammatory properties, as well as such potential negative effects of  
268 PVP-I as cellular toxicity, depend substantially on the concentration of the  
269 solution, which is consequently associated with the concentration of "free"  
270 iodine<sup>19,22</sup>. It also remains unclear as to whether increasing the amount of free  
271 iodine by increasing the amount of solvent to concentrated solution will  
272 increase the incidence of irritation<sup>17,19</sup>.

273 Some studies assessed the toxic effects of dilute concentrations of PVP-I on the  
274 survival of pre-osteoblast cells and on cellular differentiation during  
275 sterilisation, and on the preservation of allografts, which have demonstrated that  
276 alkaline phosphatase activity and osteogenic gene markers were enhanced by  
277 appropriate concentrations. It was found that this benefit is inversely  
278 proportional to even higher concentrations of PVP-I that include cytotoxicity for  
279 epithelial cells, fibroblasts and polymorphonuclear lymphocytes<sup>17,22</sup>.

280 Our findings support the notion that PVP-I solution is effective in the  
281 management of oedema and trismus when used as a coolant for the bone drilling  
282 in the mandibular lower third molar surgery, while at the same time, variation in  
283 the likelihood of inflammatory complications were significantly associated with  
284 different concentrations of solution.

285 The main limitations of the current study was its small sample size which was  
286 because of financial and logistical reasons. Further clinical trials with large

287 sample sizes are recommended in order to obtain more definite outcomes and  
288 further minimise the undesired post-operative effects on patients.

289

## 290 **Conclusion**

291 Irrigation by 3% PVP-I solution had superior efficacy in reducing post-  
292 operative trismus, oedema and patient discomfort, and also provided a better  
293 opportunity to overcome clinical challenges.

294

295 **Disclaimer:** None.

296 **Conflict of Interests:** None.

297 **Sources of Funding:** None.

298

## 299 **References**

300 1.Tuna A, Delilbasi C, Arslan A, Gurof Y, Tekkanat ZT. Do antibacterial  
301 mouthrinses affect bacteraemia in third molar surgery? A pilot study. Aust  
302 Dent J 2012;57:435–9.

303 2.Antunes AA, Avelar RL, Martins Neto EC, Frota R, Dias E. Effect of two  
304 routes of administration of dexamethasone on pain, edema, and trismus in  
305 impacted lower third molar surgery. Oral Maxillofac Surg 2011;15:217–23.

306 3.Bangbose BO, Akinwande JA, Adeyemo WL, Ladeinde AL, Arotiba GT,  
307 Ogunlewe MO. Effects of co-administered dexamethasone and diclofenac  
308 potassium on pain, swelling and trismus following third molar surgery. Head  
309 Face Med 2005;1:11.

310 4.Beukelman CJ, van den Berg AJ, Hoekstra MJ, Reimer K, Mueller S.  
311 Antiinflammatory properties of a liposomal hydrogel with povidoneiodine  
312 (Repithel) for wound healing in vitro. Burns 2008;34(6):845-55.

313 5.Hashemi HM, Mohammadi F, Hasheminasab M, Hashemi AM, Zahraei S,  
314 Hashemi TM. Effect of Low-Concentration Povidone Iodine on Postoperative

- 315 Complications After Third Molar Surgery: A Pilot Split-Mouth Study. *J Oral*  
316 *Maxillofac Surg* 2015;73(1):18-21.
- 317 6.Kumar BP, Maddi A, Ramesh KV Baliga MJ, Rao SN, Meenakshi. Is  
318 povidone-iodine a hemostyptic? A clinical study. *Int J Oral Maxillofac Surg*  
319 2006;35:765-66.
- 320 7.The antibiotic alarm. *Nature* 2013;495(7440):141.
- 321 8.Koerner JC, George MJ, Kissam EA, Rosco MG. Povidone-iodine  
322 concentration and in vitro killing time of bacterial corneal ulcer isolates. *Digit*  
323 *J Ophthalmol* 2018;24(4):24-26.
- 324 9.Jiang Y, Chen L, Zhang S, Tong T, Zhang W, Liu W, et al. Incorporation of  
325 bioactive polyvinylpyrrolidone–iodine within bilayered collagen scaffolds  
326 enhances the differentiation and subchondral osteogenesis of mesenchymal  
327 stem cells. *Acta biomaterialia* 2013;9(9):8089–98.
- 328 10. Chappi DM, Suresh KV, Patil MR, Desai R, Tauro DP, Bharani SKNS, et  
329 al. Comparison of clinical efficacy of methylprednisolone and  
330 serratiopeptidase for reduction of postoperative sequelae after lower third  
331 molar surgery. *J Clin Exp Dent*. 2015;7(2):e197-202.
- 332 11. Laureano Filho JR, Maurette PE, Allais M, Cotinho M, Fernandes C.  
333 Clinical comparative study of the effectiveness of two dosages of  
334 dexamethasone to control postoperative swelling, trismus and pain after the  
335 surgical extraction of mandibular impacted third molars. *Med Oral Patol Oral*  
336 *Cir Bucal* 2008;13(2):E129-32.
- 337 12. Pell GJ, Gregory GT. Impacted mandibular third molars: classification  
338 and modified technique for removal. *Dent Dig* 1933;39:330.
- 339 13. Rohit S, Praveen Reddy B. Efficacy of postoperative prophylactic  
340 antibiotic therapy in third molar surgery. *J Clin Diagn Res* 2014;8(5):ZC14-6.
- 341 14. Marković AB, Todorović L. Postoperative analgesia after lower third  
342 molar surgery: contribution of the use of long-acting local anesthetics, low-

- 343 power laser, and diclofenac. *Oral Surg Oral Med Oral Pathol Oral Radiol*  
344 *Endodontol* 2006;102(5):e4–e8.
- 345 15. Markovic A, Todorovic L. Effectiveness of dexamethasone and low-  
346 power laser in minimizing oedema after third molar surgery: a clinical trial.  
347 *Int J Oral Maxillofac Surg* 2007;36(3):226–9.
- 348 16. Al-Khateeb TL, Marouf HA, Mahmud MA. Clinical evaluation of  
349 dexamethasone vs. methylprednisolone for reducing postoperative  
350 inflammatory sequelae following third molar surgery amongst preschool  
351 children in Jeddah, Saudi Arabia. *Saudi Dent* 2006;8:13–8.
- 352 17. Ferguson AW, Scott JA, McGavigan J, Elton RA, McLean J, Schmidt U,  
353 et al. Comparison of 5% povidone-iodine solution against 1% povidone-  
354 iodine solution in preoperative cataract surgery antisepsis: a prospective  
355 randomised double blind study. *Br J Ophthalmol* 2003;87:163–7.
- 356 18. Asimakopoulos G, Thompson R, Nourshargh S, Lidington EA, Mason  
357 JC, Ratnatunga CP, et al. An anti-inflammatory property of aprotinin detected  
358 at the level of leukocyte extravasation. *J Thorac Cardiovasc Surg*  
359 2000;120:361–9.
- 360 19. de Jonge SW, Boldingh QJJ, Solomkin JS, Allegranzi B, Egger  
361 M, Dellinger EP et al. Systematic Review and Meta  
362 Analysis of Randomized Controlled Trials Evaluating Prophylactic Intra-  
363 Operative Wound Irrigation for the Prevention of Surgical Site Infections.  
364 *Surg Infect (Larchmt)* 2017;18(4):508-519.
- 365 20. König B, Reimer K, Fleischer W, König W. Effects of Betaisodonal on  
366 parameters of host defense. *Dermatology* 1997;195(Suppl. 2):42–8.
- 367 21. Kumar KS, Reddy GVK, Naidu G, Pandiarajan R. Role of povidone  
368 iodine in periapical surgeries: Hemostyptic and anti-inflammatory? *Ann*  
369 *Maxillofac Surg* 2011;1(2):107-11.
- 370 22. Zhao Y, Hu X, Li Z, Wang F, Xia Y, Hou S, et al. Use of  
371 polyvinylpyrrolidone-iodine solution for sterilisation and preservation

372 improves mechanical properties and osteogenesis of allografts. *Sci Rep*  
373 2016;6:38669.

374 23. Schmidlin P R, Imfeld T, Sahrman P, Tchouboukov A, Weber F E.  
375 Effect of shorttime povidone–iodine application on osteoblast proliferation  
376 and differentiation. *Open Dent* 2009;3:208–12.

377 24. Arakeri G, Brennan PA. Povidone-iodine: An anti-oedematous agent? *Int*  
378 *J Oral Maxillofac Surg* 2011;40:173.

379 25. Ader AW, Paul TL, Reinhardt W, Safran M, Pino S, McArthur W, et al.  
380 Effect of mouth rinsing with two polyvinylpyrrolidone-iodine mixtures on  
381 iodine absorption and thyroid function. *J Clin Endocrinol Metab*  
382 1998;66:632–5.

383 26. Kotsilkov K, Emilov D, Popova C. Subgingival Irrigations With  
384 Povidoneiodine As adjunctive treatment of chronic periodontitis. *Journal of*  
385 *IMAB - Annual Proceeding (Scientific Papers) Book* 2009;2:84–8.

386

387 -----

388

389

**Table1: Comparison of baseline descriptive data in 4 groups.**

	Group 1	Group 2	Group 3	Group 4	p
<b>Age</b> Mean±SD	24,55±3,33	24,75±3,45	24,60±3,92	24,5±4,01	<sup>1</sup> 0,997
<b>Gender</b> n (%)					
<b>Male</b>	10 (%50)	7 (%35)	9 (%45)	8 (%40)	<sup>2</sup> 0,872
<b>Female</b>	10 (%50)	13 (%65)	11 (%55)	12 (%60)	
<b>Relation to Ramus</b> n (%)					
<b>C1</b>	6 (%30)	9 (%45)	7 (%35)	8 (%40)	<sup>3</sup> 0,952
<b>C2</b>	9 (%45)	8 (%40)	9 (%45)	7 (%35)	
<b>C3</b>	5 (%25)	3 (%15)	4 (%20)	5 (%25)	

390

<sup>1</sup>Oneway ANOVA Test; <sup>2</sup>Chi-square Test; <sup>3</sup>Fisher Freeman Halton Test (p<0,05).

391

SD: Standard deviation

392

393 -----

394

395 **Table 2: Mouth opening was evaluated between groups and within each group**  
 396 **preoperatively and on postoperative days 2 and 7. Values are expressed as the mean.**

Time		Group1	Group 2	Group 3	Group 4	<sup>1</sup> p
		Avg±SD	Avg±SD	Avg±SD	Avg±SD	
distance	Preop	4,38±0,33	4,44±0,42	4,22±0,44	3,97±0,49	0,004
	Postop. day 2	2,52±0,37	3,14±0,48	3,5±0,46	3,3±0,44	0,001
	Postop. day 7	3,18±0,39	3,86±0,49	4,02±0,42	3,84±0,5	0,001
Inter-incisal (cm)	<sup>2</sup> p	0,001	0,001	0,001	0,001	
	Preop-Postop. day 2 <sup>3</sup> p	0,001	0,001	0,001	0,001	
	Preop-Postop. day 7 <sup>3</sup> p	0,001	0,001	0,001	0,001	
	Postop. day 2- day 7 <sup>3</sup> p	0,001	0,001	0,001	0,001	

397 <sup>1</sup>One Way ANOVA test; <sup>2</sup> Repeated measures analysis of variance; <sup>3</sup> Bonferroni Test  
 398 (p<0,05). SD: Standard deviation  
 399  
 400  
 401

402 **Table 3: Facial swelling was evaluated between groups and within each group**  
 403 **preoperatively and on postoperative days 2 and 7. Values are expressed as the mean.**

Time		Group 1	Group 2	Group 3	Group 4	<sup>1</sup> p
		Avg±SD	Avg±SD	Avg±SD	Avg±SD	
Tragus-comissure line (cm)	Preop	11,51±0,73	11,52±0,7	11,67±0,4	11,13±0,4	0,03
	Postop. day 2	12,85±0,51	12,49±0,68	12,28±0,4	11,47±0,4	0,00
	Postop. day 7	12,22±0,63	12,02±0,71	11,79±0,4	11,16±0,4	0,00
	<sup>2</sup> p	0,001	0,001	0,001	0,001	
	Preop-Postop. day 2	0,001	0,001	0,001	0,001	
	Preop-Postop. day 7	0,001	0,001	0,001	0,092	
	Postop. day 2- day 7	0,001	0,001	0,001	0,001	
Tragus-pogonion line (cm)	Preop	14,12±1,26	14,23±1,01	14,6±1,01	14,18±0,9	0,46
	Postop. day 2	15,82±0,93	15,26±1,02	15,1±1,03	14,36±0,8	0,00
	Postop. day 7	15,3±1	14,72±1,07	14,73±1	14,19±0,9	0,00
	<sup>2</sup> p	0,001	0,001	0,001	0,001	
	Preop-Postop. day 2	0,001	0,001	0,001	0,001	
	Preop-Postop. day 7	0,001	0,001	0,001	0,248	
	Postop. day 2- day 7	0,001	0,001	0,001	0,001	
C a	Preop	9,2±0,71	9,99±0,66	11,01±0,9	9,7±1,19	0,00

<b>Postop. day 2</b>	9,79±0,7	10,4±0,68	11,32±1,0	9,82±1,21	0,00
<b>Postop. day 7</b>	9,51±0,69	10,14±0,67	11,1±0,98	9,7±1,19	0,00
<sup>2</sup> <i>p</i>	0,001	0,001	0,001	0,001	
<b>Preop-Postop. day 2</b>	0,001	0,001	0,001	0,001	
<b>Preop-Postop. day 7</b>	0,001	0,001	0,018	1	
<b>Postop. day 2- day 7</b>	0,001	0,001	0,001	0,001	

404 <sup>1</sup>One Way ANOVA test; <sup>2</sup> Repeated measures analysis of variance; <sup>3</sup> Bonferroni Test  
 405 (p<0,05).

406 SD: Standard deviation.

407

Provisionally Accepted for Publication